Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib

References

• Aquilante CL, Niemi M, Gong L, et al. (2013). PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics 23:721–8
   PubMed Web of Science ®Google Scholar
• Berglund E, Ubhayasekera SJ, Karlsson F, et al. (2014). Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells. Anticancer Drugs 25:415–22
   PubMed Web of Science ®Google Scholar
• Bouchet S, Titier K, Moore N, et al. (2013). Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 27:690–7
   PubMed Web of Science ®Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607
   PubMedGoogle Scholar
• Daily EB, Aquilante CL. (2009). Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10:1489–510
   PubMed Web of Science ®Google Scholar
• de Wit D, Guchelaar HJ, den Hartigh J, et al. (2015). Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today 20:18–36
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, Backman JT. (2012). Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165:2787–98
   PubMed Web of Science ®Google Scholar
• Filppula AM, Neuvonen M, Laitila J, et al. (2013). Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 41:50–9
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu D, Wang H, et al. (2010). Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions. Xenobiotica 40:467–75
   PubMed Web of Science ®Google Scholar
• Gotta V, Bouchet S, Widmer N, et al. (2014). Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38:764–72
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F, et al. (2005). Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503–12
   PubMed Web of Science ®Google Scholar
• Houston JB, Galetin A. (2005). Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351–60
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis–Menten model. Drug Metab Dispos 28:246–54
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. (2014). Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89:547–56
   PubMed Web of Science ®Google Scholar
• Josephs DH, Fisher DS, Spicer J, Flanagan RJ. (2013). Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 35:562–87
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Fuhr U, et al. (2008). Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 9:277–88
   PubMed Web of Science ®Google Scholar
• Klees TM, Sheffels P, Dale O, Kharasch ED. (2005). Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos 33:303–11
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–8
   PubMed Web of Science ®Google Scholar
• Li Y, Coller JK, Hutchinson MR, et al. (2013). The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos 41:1264–72
   PubMed Web of Science ®Google Scholar
• Linch M, Claus J, Benson C. (2013). Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther 6:1011–23
   PubMed Web of Science ®Google Scholar
• Maino E, Sancetta R, Viero P, et al. (2014). Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther 14:723–40
   PubMed Web of Science ®Google Scholar
• Marull M, Rochat B. (2006). Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 41:390–404
   PubMed Web of Science ®Google Scholar
• Muschler E, Lal J, Jetter A, et al. (2009). The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol 105:374–9
   PubMed Web of Science ®Google Scholar
• Nebot N, Crettol S, d'Esposito F, et al. (2010). Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161:1059–69
   PubMed Web of Science ®Google Scholar
• Niemi M, Leathart JB, Neuvonen M, et al. (2003). Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380–7
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8
   PubMed Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, et al. (2004). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158–62
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496–9
   PubMed Web of Science ®Google Scholar
• Rochat B, Zoete V, Grosdidier A, et al. (2008). In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos 29:103–18
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Sansen S, et al. (2008). Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227–37
   PubMed Web of Science ®Google Scholar
• Stage TB, Christensen MM, Feddersen S, et al. (2013). The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 23:219–27
   PubMed Web of Science ®Google Scholar
• Tan KL, Ankathil R, Gan SH. (2011). Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci 879:3583–91
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Backman JT. (2008). Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36:73–80
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Karlsson MO, et al. (2007). Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13:7394–400
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. (2011). Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546–54
   PubMed Web of Science ®Google Scholar
• Wattanachai N, Polasek TM, Heath TM, et al. (2011). In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815–24
   PubMed Web of Science ®Google Scholar
• Widmer N, Bardin C, Chatelut E, et al. (2014). Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies. Eur J Cancer 50:2020–36
   PubMed Web of Science ®Google Scholar
• Yu L, Shi D, Ma L, et al. (2013). Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos 34:278–87
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar
• Zanger UM, Vilbois F, Hardwick JP, Meyer UA. (1988). Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447–54
   PubMed Web of Science ®Google Scholar